After raising more than $30 million in its initial financing, oncology biotech Karyopharm Therapeutics Inc. is adding to its cash runway with a Series B that brought in $48.2 million. The Natick, Mass.-based company will use the new funds to push its lead cancer asset forward in multiple indications.
Karyopharm, which was founded in 2008, has been financed largely by a private investor until now. In November 2010, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?